File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Dental Implant Treatment in Patients Treated with Systemic Ivdelivery of Zoledronate (Bisphosphonates) for the Treatment of Osteoporosis

TitleDental Implant Treatment in Patients Treated with Systemic Ivdelivery of Zoledronate (Bisphosphonates) for the Treatment of Osteoporosis
Authors
Issue Date2012
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1875-595X
Citation
FDI Annual World Dental Congress, Hong Kong China, 29 August-1 September 2012. In International Dental Journal, 2012, v. 62 n. Suppl. 1, p. 43, abstract no. FC047 How to Cite?
AbstractIntroduction: Intravenous (IV) administration of Bisphosphobates has in general been considered an absolute contraindication for elective surgery, including dental implant placement, due to the increased risk for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). Materials and methods: Reporting the case of a patient who received a dental implant while in treatment with iv Zoledronic Acid, this presentation aims to review the current evidence and identify the factors of importance for decision-making in such cases. Discussion: The evidence with regards to IV administration of Bisphosphonates, mainly originates from patients treated for various forms of metastatic cancer, which requires a medication scheme significantly different than in the treatment of osteoporosis. As iv infusion of Bisphosphonates is becoming an increasingly utilised treatment modality for the treatment of Osteoporosis, it is important to identify the factors of importance for clinical decision making in such cases and differentiate from the general risks of procedures related to the treatment of cancer.
DescriptionSession Theme: Implantology – Oral Medicine
Persistent Identifierhttp://hdl.handle.net/10722/186516
ISSN
2015 Impact Factor: 0.967
2015 SCImago Journal Rankings: 0.512

 

DC FieldValueLanguage
dc.contributor.authorMattheos, Nen_US
dc.contributor.authorCaldwell, Pen_US
dc.contributor.authorReher, Pen_US
dc.date.accessioned2013-08-20T12:12:14Z-
dc.date.available2013-08-20T12:12:14Z-
dc.date.issued2012en_US
dc.identifier.citationFDI Annual World Dental Congress, Hong Kong China, 29 August-1 September 2012. In International Dental Journal, 2012, v. 62 n. Suppl. 1, p. 43, abstract no. FC047en_US
dc.identifier.issn0020-6539-
dc.identifier.urihttp://hdl.handle.net/10722/186516-
dc.descriptionSession Theme: Implantology – Oral Medicine-
dc.description.abstractIntroduction: Intravenous (IV) administration of Bisphosphobates has in general been considered an absolute contraindication for elective surgery, including dental implant placement, due to the increased risk for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). Materials and methods: Reporting the case of a patient who received a dental implant while in treatment with iv Zoledronic Acid, this presentation aims to review the current evidence and identify the factors of importance for decision-making in such cases. Discussion: The evidence with regards to IV administration of Bisphosphonates, mainly originates from patients treated for various forms of metastatic cancer, which requires a medication scheme significantly different than in the treatment of osteoporosis. As iv infusion of Bisphosphonates is becoming an increasingly utilised treatment modality for the treatment of Osteoporosis, it is important to identify the factors of importance for clinical decision making in such cases and differentiate from the general risks of procedures related to the treatment of cancer.-
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1875-595X-
dc.relation.ispartofInternational Dental Journalen_US
dc.rightsInternational Dental Journal. Copyright © John Wiley & Sons Ltd.-
dc.titleDental Implant Treatment in Patients Treated with Systemic Ivdelivery of Zoledronate (Bisphosphonates) for the Treatment of Osteoporosisen_US
dc.typeConference_Paperen_US
dc.identifier.emailMattheos, N: mattheos@hku.hken_US
dc.identifier.authorityMattheos, N=rp01662en_US
dc.identifier.doi10.1111/j.1875-595X.2012.00135.xen_US
dc.identifier.hkuros218257en_US
dc.identifier.hkuros215919-
dc.identifier.volume62en_US
dc.identifier.issueSuppl. 1en_US
dc.identifier.spage43, abstract no. FC047en_US
dc.identifier.epage43, abstract no. FC047en_US
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats